Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis

Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis

Abstract Biological therapies have dramatically improved the therapeutic landscape of psoriatic arthritis (PsA); however, 40–50% of patients are primary non-responders with response rates declining significantly with each successive biological therapy. Therefore, there is a pressing need to develop...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sara Rahmati, Darren D. O’Rielly, Quan Li, Dianne Codner, Amanda Dohey, Kari Jenkins, Igor Jurisica, Dafna D. Gladman, Vinod Chandran, Proton Rahman
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/89afa7b431d842f397da1b39a9b64a04
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares